Acute Lymphoblastic Leukemia Clinical Trial
Official title:
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
The primary aim of this protocol is to evaluate if the one-year survival is significantly improved in the group of patients who receive a T-cell replete haploidentical donor hematopoietic cell transplant (HCT) with a novel reduced intensity conditioning regimen. Study population will consist of patients (21 years or under) with hematologic malignancies that have relapsed or are refractory after prior allogeneic transplant. Toxicity will be evaluated by the rate of transplant related mortality and the rates of moderate and severe graft-versus-host disease (GvHD) at day 100. The investigators will describe event-free, and disease-free survival at one year, as well as the rates of hematopoietic recovery and donor engraftment and study comprehensively immune reconstitution following T-cell replete haploidentical transplantation.
Patients with refractory hematologic malignancies, including those who develop recurrent
disease after allogeneic hematopoietic cell transplantation, have a dismal prognosis.
Historically, both regimen-related mortality and disease recurrence have been significant
causes of treatment failure in this heavily pre-treated patient population. Our institution
has utilized mismatched family member (haploidentical) donors for these patients for a
number of years for the following reasons: (1) Only 30% of patients have matched related
donors available; (2) transplantation can be performed more rapidly since the time to
unrelated donor transplantation averages 3 to 4 months; (3) no other curative treatment
options are available. These therapeutic interventions have been largely successful given
the dismal prognosis in this patient group; however disease recurrence remains the most
significant cause of treatment failure. To provide maximum benefit for this challenging
population, the goals of a therapeutic transplant protocol should include: (1) a
conditioning regimen that is well tolerated, even in a heavily pre-treated population; but
it should also provide substantial antileukemia effects, and (2) should establish rapid
immune recovery such that the patient may benefit from graft versus leukemia effect and
early protection from life threatening infections while also limiting dangerous and
counter-productive graft versus host disease.
The primary aim of this protocol will be to evaluate if the one-year survival is
significantly improved in the group of patients receiving T-cell replete haploidentical
donor HCT with a novel clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, and
ATG based reduced intensity conditioning regimen whose hematologic malignancy has relapsed
or is refractory after prior allogeneic transplant. Toxicity will be evaluated by the rate
of transplant related mortality and the rates of moderate and severe graft versus host
disease at day 100. The investigators will also describe event-free, and disease-free
survival at one year, as well as the rates of hematopoietic recovery and donor engraftment.
Additionally, the investigators will study comprehensively immune reconstitution following
T-cell replete haploidentical transplantation.
PRIMARY OBJECTIVE:
- Evaluate if the one-year survival is significantly improved in a group of children
receiving a therapeutic regimen for high-risk hematologic malignancy that is relapsed
or refractory despite previous allogeneic hematopoietic cell transplantation (HCT)
using a novel reduced intensity conditioning and T-cell replete haploidentical donor
hematopoietic stem cell plus NK cell transplantation.
SECONDARY OBJECTIVES:
- Estimate the incidence of malignant relapse, event-free survival, and disease free
survival (DFS) at one-year post-transplantation.
- Estimate incidence and severity of acute and chronic (GVHD).
- Estimate the rate of transplant related mortality (TRM) in the first 100 days after
transplantation.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |